RightFit Trial Directory

Breast Cancer clinical trials in Seattle, WA

28 recruiting breast cancer studies with a site in Seattle, WA.

All trials in Seattle, WA · All Breast Cancer trials

RecruitingPhase 3NCT06841354

A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

Sponsor: Merck Sharp & Dohme LLC

Seattle, WA · +38 more sites

RecruitingPhase 3NCT07174336

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

Sponsor: Eli Lilly and Company

Edmonds, WA · Everett, WA · Renton, WA · +126 more sites

RecruitingPhase 3NCT06790693

A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

Sponsor: Hoffmann-La Roche

Edmonds, WA · Everett, WA · Seattle, WA · +59 more sites

RecruitingPhase 2NCT06760819

A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

Sponsor: Bayer

Seattle, WA · +10 more sites

RecruitingPhase 2NCT06172478

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

Sponsor: Daiichi Sankyo

Seattle, WA · +12 more sites

RecruitingPhase 1NCT07222267

An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors

Sponsor: BeOne Medicines

Seattle, WA · +5 more sites

RecruitingPhase 2NCT06179303

Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

Sponsor: University of Washington

Seattle, WA · +2 more sites

RecruitingNot applicableNCT07214532

Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer

Sponsor: Natera, Inc.

Puyallup, WA · Seattle, WA · Tacoma, WA · +46 more sites

RecruitingNot applicableNCT06085833

ARTIDIS Nanomechanical Generated Measurements for Early Breast Lesions

Sponsor: ARTIDIS AG

Seattle, WA · +3 more sites

RecruitingPhase 1NCT05983432

Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

Sponsor: SystImmune Inc.

Seattle, WA · +21 more sites

RecruitingPhase 3NCT06492616

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

Sponsor: Stemline Therapeutics, Inc.

Edmonds, WA · Issaquah, WA · Kirkland, WA · +173 more sites

RecruitingPhase 1 / Phase 2NCT06657222

First in Human Study of TUB-030 in Patients With Advanced Solid Tumors

Sponsor: Gilead Sciences

Seattle, WA · +12 more sites

RecruitingPhase 3NCT05879926

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

Sponsor: NRG Oncology

Aberdeen, WA · Bellevue, WA · Bellingham, WA · +1223 more sites

RecruitingPhase 3NCT05812807

Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

Sponsor: Alliance for Clinical Trials in Oncology

Bellevue, WA · Edmonds, WA · Issaquah, WA · +825 more sites

RecruitingPhase 2NCT07078604

A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer

Sponsor: University of Washington

Seattle, WA

RecruitingPhase 1NCT06562192

Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers

Sponsor: Novartis Pharmaceuticals

Seattle, WA · +8 more sites

RecruitingPhase 1NCT05098210

Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer

Sponsor: Fred Hutchinson Cancer Center

Seattle, WA

RecruitingPhase not listedNCT06551116

QuantifyHER: Quantitative Immunofluorescence and/or RT-qPCR for Measuring HER2 in HER2-low Metastatic Breast Cancer

Sponsor: Abramson Cancer Center at Penn Medicine

Seattle, WA · +36 more sites

RecruitingPhase 1NCT04389632

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

Sponsor: Seagen, a wholly owned subsidiary of Pfizer

Bonney Lake, WA · Edmonds, WA · +103 more sites

RecruitingPhase 3NCT05696626

Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

Sponsor: LeonaBio

Seattle, WA · +35 more sites

RecruitingPhase 3NCT04852887

De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)

Sponsor: NRG Oncology

Bellingham, WA · Edmonds, WA · Issaquah, WA · +809 more sites

RecruitingPhase 2NCT07112053

A Vaccine (STEMVAC) With Standard Endocrine-Based Therapy or Chemotherapy for the Treatment of Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer

Sponsor: University of Washington

Seattle, WA

RecruitingPhase 1 / Phase 2NCT06395519

A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

Sponsor: 858 Therapeutics, Inc.

Seattle, WA · +13 more sites

RecruitingPhase 1NCT06778863

A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

Sponsor: Clasp Therapeutics, Inc.

Seattle, WA · +20 more sites

RecruitingPhase 3NCT06435429

A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer

Sponsor: Jazz Pharmaceuticals

Seattle, WA · +47 more sites

RecruitingPhase 3NCT05929768

Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer

Sponsor: SWOG Cancer Research Network

Aberdeen, WA · Bellevue, WA · Bellingham, WA · +952 more sites

RecruitingPhase 1NCT05107674

A Study of NX-1607 in Adults With Advanced Malignancies

Sponsor: Nurix Therapeutics, Inc.

Seattle, WA · +9 more sites

RecruitingPhase 1 / Phase 2NCT06682793

A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression

Sponsor: A2 Biotherapeutics Inc.

Seattle, WA · +9 more sites

Listings come from ClinicalTrials.gov and are provided for information only. Always confirm eligibility with the study team and talk with your doctor before making decisions about your care.